Literature DB >> 29882202

Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients.

Laurent Lafarge1, Fouzi Khayi1, Anis Bel-Kamel1, Nicolas Charhon2, Laura Sarfati2, Benoit Falquet1, Michel Ducher3,4, Laurent Bourguignon1,5,6.   

Abstract

BACKGROUND: Oral vitamin K antagonists (VKAs) are commonly used in older adults. To ensure the efficiency and safety of these drugs, the international normalized ratio (INR) must be monitored. The time in therapeutic range (TTR) is an internationally recommended assessment of the anticoagulation quality.
OBJECTIVE: Our study aimed to assess the TTR of VKAs in a hospitalized geriatric population and identify factors associated with low TTR.
METHODS: This was a multicenter retrospective study of data from 1899 patients with a mean age of 87 years between 2013 and 2015 in the geriatric units of four French hospitals. The data collection consisted of 2450 VKA prescriptions. We excluded prescriptions with a duration of < 7 days, monitoring with fewer than two INR values and patients with prosthetic heart valves. TTR was assessed using the Rosendaal method. Factors associated with a low TTR (< 50%) were assessed using a non-parametric method.
RESULTS: The mean TTR observed in this population was 42.6%. The TTR was < 50% for 62.5% of the patients included in this study. Significant associations were found between TTR < 50% and aspartate transaminase (AST), alkaline phosphatase (ALT), thyroid-stimulating hormone (TSH), prescription duration, fluconazole instauration, hemoglobin, and C-reactive protein (CRP).
CONCLUSIONS: Both our results and those in the literature indicate that TTR in geriatric populations is lower than that in the general population. Most patients had an insufficient TTR, exposing them to an increased risk of thromboembolic and hemorrhagic events. These data provide a perspective on poor-quality anticoagulation and illustrates the difficulty of using VKAs in geriatric patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29882202     DOI: 10.1007/s40266-018-0551-5

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  36 in total

1.  Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries.

Authors:  François-Emery Cotté; Hicham Benhaddi; Isabelle Duprat-Lomon; Adam Doble; Nick Marchant; Alexia Letierce; Michael Huguet
Journal:  Clin Ther       Date:  2014-08-21       Impact factor: 3.393

2.  Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation.

Authors:  Pak-Hei Chan; Wen-Hua Li; Jo-Jo Hai; Esther W Chan; Ian C K Wong; Hung-Fat Tse; Gregory Y H Lip; Chung-Wah Siu
Journal:  Can J Cardiol       Date:  2015-11-06       Impact factor: 5.223

3.  Major Haemorrhage during Vitamin K Antagonist Treatment: The Influence of Thyroid Hormone Levels.

Authors:  Jan Debeij; Suzanne C Cannegieter; Bregje van Zaane; Anton P van Zanten; Frits R Rosendaal; Victor E A Gerdes; Pieter H Reitsma; Olaf M Dekkers
Journal:  Eur Thyroid J       Date:  2014-02-28

4.  The management of atrial fibrillation: summary of updated NICE guidance.

Authors:  Clare Jones; Vicki Pollit; David Fitzmaurice; Campbell Cowan
Journal:  BMJ       Date:  2014-06-19

5.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld
Journal:  Eur J Cardiothorac Surg       Date:  2016-09-23       Impact factor: 4.191

Review 6.  Atrial fibrillation and heart failure in the elderly.

Authors:  Pedram Kazemian; Gavin Oudit; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

7.  Major bleeding risk associated with warfarin and co-medications in the elderly population.

Authors:  Agnes I Vitry; Elizabeth E Roughead; Emmae N Ramsay; Adrian K Preiss; Philip Ryan; Andrew L Gilbert; Gillian E Caughey; Sepehr Shakib; Adrian Esterman; Ying Zhang; Robyn A McDermott
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-10       Impact factor: 2.890

8.  STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation.

Authors:  P Gallagher; C Ryan; S Byrne; J Kennedy; D O'Mahony
Journal:  Int J Clin Pharmacol Ther       Date:  2008-02       Impact factor: 1.366

9.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

10.  International Normalized Ratio Variability: A Measure of Anticoagulation Quality or a Powerful Mortality Predictor.

Authors:  Gabriel Vanerio
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-07-29       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.